Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Proceedings of the 8th Global Arthritis Research Network (GARN) Meeting and 1st Bio-Rheumatology International Congress (BRIC)

Open Badges Poster presentation

SNP algorithms for prediction of efficacy and adverse events of abatacept (ABT)

James E Middleton1*, Tsukasa Matsubara12, Keiko Funahashi12, Satoru Koyano1, Takafumi Hagiwara2, Takako Miura2, Kosuke Okuda2, Takeshi Nakamura2, Mitsuyoshi Iwahashi3, Tomomi Tsuru4, Shoichi Uchimura5 and Shigeru Honjo6

  • * Corresponding author: James E Middleton

Author Affiliations

1 Research Institute of Joint Diseases, Kobe, Japan

2 Matsubara Mayflower Hospital, Kato, Japan

3 Higashi-Hiroshima Memorial Hospital, Higashi-Hiroshima, Japan

4 PS Clinic, Fukuoka, Japan

5 Kanzaki Municipal General Hospital, Japan

6 Honjo Rheumatism Clinic, Japan

For all author emails, please log on.

Arthritis Research & Therapy 2012, 14(Suppl 1):P48  doi:10.1186/ar3649

The electronic version of this article is the complete one and can be found online at:

Published:9 February 2012

© 2012 Middleton et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Abatacept (ABT), a CTLA4-Ig fusion protein, which inhibits the binding of CD28 and CD80 agents targeted to T-cells, is a relatively new biological agent for RA treatment in Japan. However, there is no method for prediction of responders, non-responders, or adverse events which can occur during treatment. We established SNP algorithms for prediction of responders (R) or non-responders (NR), and adverse events in ABT-treated patients.

Materials and methods

Forty-six RA patients treated with ABT were included in this study. Efficacy was assessed by DAS28 (CRP) at 48 weeks after the initial treatment. Any adverse events that may have been related to ABT administration and observed at 48 weeks of this long-term administration and during phase II were considered to be side effects. Genome-wide SNP genotyping was performed by Illumina Human610-Quad chip technology. Case-control analyses between 598,821 SNPs and responsiveness or occurrence of adverse events were examined by Fisher's exact test. We selected 10 SNPs associated with ABT-responsiveness, remission, and adverse events (p < 0.0001). We scored the relationship between each SNP and responsiveness, the estimated total score of 10 SNPs (estimated scoring in each SNP was as follows: homo allele in the majority in responders: +1 point, hetero allele: 0 points, and homo allele in the majority of non-responders: -1 point), and then examined relationships between responders and non-responders, remission and non-remission, and occurrence of adverse events, plus or minus, and the total score.


Accuracy, specificity, and sensitivity of the algorithm for responsiveness of abatacept ranged from 90-96%. For remission, accuracy, specificity and sensitivity of the algorithm ranged from 91-97%. For adverse events, accuracy, specificity and sensitivity of the algorithm ranged from 95-100%. It is therefore suggested that the SNP algorithms can predict responders and adverse events prior to the initiation of treatment with abatacept.


These highly accurate algorithms using SNP analysis may be useful in the prediction of responsiveness and adverse events before treatment with abatacept, and in this way can contribute to future tailor-made treatment with biologic agents.